Rocket Pharmaceuticals, Inc
Price
FilingsNewest: 8-K, Material agreementOct 6 →Insiders1 insider bought $34,400 in 1 open-market buy. 5 insiders sold $546,347, 0 of 22 sales on a 10b5-1 plan.→HoldersRTW Investments 16.1%BlackRock 9.1%Vanguard Portfolio 5.3%→Financing →PeersClosest companies: LXEO, RARE, MGX→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$17.3Mlast 12 months
- Operating cash flow
- −$179.6Mlast 12 months
- Cash and equivalents
- $224.5Mat the last balance sheet
- Shares outstanding
- 109.5M shareson issue